Weight Loss Rebounding: The Challenges of Stopping Obesity Drugs
Semaglutide, under the brand names Wegovy® and Ozempic®, has surged in popularity for its ability to help people lose weight and reduce the risk of
Semaglutide, under the brand names Wegovy® and Ozempic®, has surged in popularity for its ability to help people lose weight and reduce the risk of
The Danish pharmaceutical company Novo Nordisk has announced promising early results for amycretin, a novel oral weight loss medication. This new drug appears to outperform
NodThera, a biotech company based in Cambridge, England, is developing a new class of medicines that inhibit the NOD-, LRR- and pyrin domain-containing protein 3
As GLP-1 receptor agonist injections continue to gain acceptance as effective solutions for weight management and cardiovascular health, a tiny drug-delivering implant from Vivani Medical
Glucagon-like peptide-1 (GLP-1) receptor agonists are arguably the hottest topic in medical innovation. The drugs semaglutide and tirzepatide, known under brand names like Ozempic, Wegovy,
Research using data from a large U.S. health survey has disrupted conventional thinking about body mass index (BMI) and its role in predicting all-cause mortality.
Lurking among the vast genetic holdings of the UK Biobank data, researchers uncovered a potential gem — a gene variant linked to cardiometabolic health. Conditions
Gene therapy offers hope for treating a wide range of inherited and acquired diseases and conditions, ranging from muscular dystrophy to obesity. Gene therapy for
Recent headlines have been abuzz with the groundbreaking weight loss results achieved with the injectable drug semaglutide, demonstrating the potential for people with obesity to
Clinical trial data has demonstrated that the anti-obesity drug semaglutide, marketed for obesity and diabetes, could offer substantial protection against heart disease. The results could
For years, obesity and weight gain have been blamed on the “calorie concept”: the idea that obesity is caused by taking in more calories (through
Danish pharmaceutical giant Novo Nordisk changed the game last year, presenting data that suggested one of the company’s diabetes drugs was also highly effective at
Semaglutide, under the brand names Wegovy® and Ozempic®, has surged in popularity for its ability to help people lose weight and reduce the risk of
The Danish pharmaceutical company Novo Nordisk has announced promising early results for amycretin, a novel oral weight loss medication. This new drug appears to outperform
NodThera, a biotech company based in Cambridge, England, is developing a new class of medicines that inhibit the NOD-, LRR- and pyrin domain-containing protein 3
As GLP-1 receptor agonist injections continue to gain acceptance as effective solutions for weight management and cardiovascular health, a tiny drug-delivering implant from Vivani Medical
Glucagon-like peptide-1 (GLP-1) receptor agonists are arguably the hottest topic in medical innovation. The drugs semaglutide and tirzepatide, known under brand names like Ozempic, Wegovy,
Research using data from a large U.S. health survey has disrupted conventional thinking about body mass index (BMI) and its role in predicting all-cause mortality.
Lurking among the vast genetic holdings of the UK Biobank data, researchers uncovered a potential gem — a gene variant linked to cardiometabolic health. Conditions
Gene therapy offers hope for treating a wide range of inherited and acquired diseases and conditions, ranging from muscular dystrophy to obesity. Gene therapy for
Recent headlines have been abuzz with the groundbreaking weight loss results achieved with the injectable drug semaglutide, demonstrating the potential for people with obesity to
Clinical trial data has demonstrated that the anti-obesity drug semaglutide, marketed for obesity and diabetes, could offer substantial protection against heart disease. The results could
For years, obesity and weight gain have been blamed on the “calorie concept”: the idea that obesity is caused by taking in more calories (through
Danish pharmaceutical giant Novo Nordisk changed the game last year, presenting data that suggested one of the company’s diabetes drugs was also highly effective at
Delaware Technology Park,
3 Innovation Way,
Newark, DE 19711
"*" indicates required fields
Emails are serviced by Constant Contact. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.